Table 1.
Clinical characteristics.
| LTRs | KTRs | ||
|---|---|---|---|
| Patient Characteristics | n (%) | p-Value | |
| Number of patients | 23 (100) | 16 (100) | |
| PTLD incidence rate (per 1000 patient-years) Mean age at Tx (years) [SD] |
2.1 | 0.8 | |
| 43.7 (12.0) | 36.3 (20.7) | 0.21 | |
| Males Females |
13 (56.5) | 11 (68.8) | 0.456 |
| 10 (43.5) | 5 (31.3) | 0.456 | |
| KT+LTRs Retransplantation |
1 (4.4) | 1 (6.3) | 1.0 |
| 1 (4.4) | 1 (6.3) | 1.0 | |
| IS Treatment | |||
| Induction | |||
| Anti-CD25 | 12 (52.2) | 3 (18.8) | 0.076 |
| ATG | 0 (0) | 1 (6.3) | 0.853 |
| Acute rejection | |||
| Total | 8 (34.8) | 5 (31.3) | 0.329 |
| 1 (4.4) no data | 2 (12.5) no data | ||
| GCS treated | 8 (34.8) | 5 (31.3) | 0.984 |
| ATG treated | 1 (4.4) | 0 (0) | 0.456 |
| Maintenance | |||
| Monotherapy | 4 (17.4) | 0 (0) | 0.052 |
| Double drug therapy | 12 (52.2) | 6 (37.5) | 0.381 |
| Triple drug therapy | 7 (30.4) | 10 (62.5) | 0.052 |
| GCS | 14 (60.9) | 13 (81.3) | 0.428 |
| CsA | 2 (8.7) | 8 (50) | 0.004 * |
| TAC | 21 (91.3) | 6 (37.5) | <0.001 * |
| AZA | 1 (4.4) | 5 (31.3) | 0.025 * |
| MMF | 11 (47.8) | 10 (62.5) | 0.255 |
| Viral Replication | LTRs | KTRs | p-Value |
| EBV DNA | 10 (43.2) | 10 (62.5) | 0.053 |
| 5 (21.7) no data | 5 (31.3) no data | ||
| CMV DNA | 0 (0) | 2 (12.5) | 0.093 |
| HBV DNA | 2 (8.7) | 1 (6.3) | 0.805 |
| HCV RNA | 5 (21.7) | 1 (6.3) | 0.201 |
ATG—anti-thymocyte globulin, AZA—azathioprine, CMV—cytomegalovirus, CsA—cyclosporin, EBV—Epstein-Barr virus, GCs—glucocorticosteroids, HBV—hepatitis B virus, HCV—hepatitis C virus, KT+LTRs—non-simultaneous kidney and liver transplant recipients, KTRs—kidney transplant recipients, LTRs—liver transplant recipients, MMF—mycophenolate mofetil, TAC—tacrolimus (Mann–Whitney U-test for comparison between KTRs and LTRs), * p < 0.05.